Roivant Shares Rise After Strong Phase 3 Results for Brepocitinib in Uveitis
Positive CLARITY Phase 3 data for brepocitinib in uveitis lifts Roivant stock. Median time to treatment failure exceeded 48 weeks.
/ 6 items
#ROIV↓
Immunovant Ends Cutaneous Lupus Study After IMVT-1402 Fails to Beat Placebo
Immunovant ends IMVT-1402 in cutaneous lupus after a 57-patient study missed its CLASI-A primary endpoint. Other programs remain on track.
Roivant Advances Mosliciguat to Phase 3 After Strongest PVR Reduction Yet in PH-ILD
Mosliciguat cut PVR 56.3% vs placebo in Phase 2 PH-ILD, improved 6-minute walk, and advanced to Phase 3. Shares jumped on the data.
Lisraya Wins FDA Approval as First Major Treatment Advance in Decades for Dermatomyositis
Newly approved Lisraya could become a blockbuster. J.P. Morgan calls dermatomyositis highly attractive and sees $2B+ U.S. peak sales.
Immunovant’s Batoclimab Flops in Phase 3 Thyroid Eye Disease Trials
Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.
Moderna Pays Up to $2.25 Billion to End COVID Vaccine Patent War
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.